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Introduction: Safety signals regarding drug effects on cardiac con-
ductivity have been found after the approval of medicines, despite 
evidence suggesting that they could be deemed safe during develop-
ment. Such a discrepancy may be caused by the known differences 
between real-life conditions and the so-called clinical trial population, 
which represents a subset of the target patient population, as defined 
by the many inclusion and exclusion criteria in clinical protocols. No 
formal quantitative method is available to assess the implications of 
differences betwen experimental conditions and therapeutic use of 
the drug. This study demonstrates the relevance of pharmacokinetic-
pharmacodynamic (PKPD) relationships to characterize drug-induced 
QTc-interval prolongation and to assess the implications discrepan-
cies between clinical trials and real life conditions.
Patients (or Materials) and Methods: d,l-sotalol data from healthy 
subjects and from the Rotterdam Study cohort were used as paradigm 
compound to assess treatment response in a Phase I setting and in 
real-life situation, respectively. Using not-trial-simulation principles 
and nonlinear mixed effects modeling, drug-induced effects were esti-
mated across populations to discriminate the potential implications 
of other relevant factors.
Results: Inclusion criteria were shown to restrict the representa-
tiveness of the trial population compared with real-life conditions. 
A significant part of the typical patient population was excluded 
from trials based on weight and baseline QT-interval measurements. 
Relative risk was statistically different between sotalol users with 
and without heart failure, hypertension, diabetes, and myocardial 
infarction. Although drug-induced effects do cause an increase in 
relative risk of QT interval prolongation, the presence of diabetes 
represented an increase in relative risk from 4.0 to 6.5, whereas for 
myocardial infarction it increased to 15.5 (P < 0.01).
Conclusion: Our results show that drug-induced effects on QTc-
interval do not fully explain the distribution of QTc values observed 
in the population. The increased prevalence of high QTc values in a 
real-life population can be assigned to comorbidities and concomitant 
medications. This discrepancy substantiates the need to account for 
these factors when evaluating cardiovascular risk of novel medicinal 
products. Moreover, the concept of not-in-trial simulations can be 
used as a tool for risk management, integrating pharmacokinetic-
pharmacodynamic relationships as the basis for discriminating 
drug-specific properties from other relevant factors in noncontrolled 
settings.
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Introduction: The clinical pharmacist has recently been involved in 
clinical work as a member of the Infectious Disease Committee (IDC) 
to optimize the appropriate use of antibiotics. The objective of this 
study is to evaluate the contribution of the clinical pharmacist in this 
multidisciplinary team.
Patients (or Materials) and Methods: A 5-month prospective study 
in a private hospital of 150 beds. The antibiotic treatment of each 
patient was reviewed by the clinical pharmacist, within the first 24 
hours after prescription, to detect/prevent Drug-Related Problems 
(DRP): adverse drug reactions, irrational drug utilization, and thera-
peutic failure. Furthermore, a pharmacotherapeutic follow-up was 
made until hospital discharge. The clinical pharmacist called the 
physician to make a recommendation when DRP were detected or 
suspected. Patient medical records and laboratory and microbiologi-
cal reports were used as sources of information. Creatinine clearance 
was calculated with the Crockcroft-Gault equation. Patient’s demo-
graphic data, description of pharmacologic interventions, and their 
acceptance were registered daily in a specific database.
Results: The study included 112 patients with a mean age of 76.3 
(15.1) years (10-99); 57 were women (50.9%). The clinical pharma-
cist made 163 pharmacologic interventions (range, 1–11 interven-
tions per patient), 42 (25.8%) having previously been agreed on 
with the other members of the IDC. The description of these inter-
ventions was as follows: drug choice and therapeutic de-escalation 
(n = 20 [12.3%]), excessive duration of antibiotic therapy (n = 22 
[13.5%]), sequential therapy (n = 23 [14.1%]), and dose adjust-
ment due to pharmacokinetic/pharmacodynamic parameters (n = 
18, 11%), kidney dysfunction (n = 69 [42.3%]) or obesity (n = 11 
[6.8%]). These drugs were penicillins (n = 48 [29.4%]), quinolones 
(n = 46 [28.2%]), carbapenems (n = 16 [9.8%]), cephalosporins 
(n = 16 [9.8%]), aminoglycosides (n = 7, 4.3%), oxazolidinones (n = 
5 [3.1%]), macrolides (n = 4 [2.5%]) and others (n = 21 [12.9%]). 
Intravenous administration was the main route (n = 142 [87.1%]) 
while oral administration was used in few cases (n = 21 [12.9%]). 
Finally, 133 (81.6%) pharmacologic interventions were accepted.
Conclusion: The contribution of the clinical pharmacist in the multi-
disciplinary team is becoming increasingly valuable and may improve 
the quality of antibiotic use. The high acceptance of this work seems 
to show that multidisciplinary teams are needed, with the objective 
that patients receive the safest and most effective pharmacological 
treatment as possible.
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